Ingredient · Evidence grade C

Ammonium succinate (Amberen) for menopause: evidence, studies and safety

Last updated · 4 studies summarized

C Short answer: Amberen's ammonium-succinate blend has been studied for common menopause symptoms* in two placebo-controlled trials and one open-label study, all linked to the manufacturer. The amount of each component is not disclosed.

Key facts

Evidence gradeC C
Use studiedmenopausal symptoms
Trials2 identical placebo RCTs (pooled n=227) + 1 open-label combo study (n=106)
Participants227 randomized
What reviews concludeOnly manufacturer-linked pooled analysis (2019).
The Menopause Society (2023)Not recommended (Level II) – limited, manufacturer-sponsored.
Also known asAmberen, succinate

Grades: A strong · B moderate · C limited · D none or negative. How we grade.

Every study we reviewed

Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.

  • Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial.

    Radzinskii VE, Kuznetsova IV, Uspenskaya YB et al. · Gynecol Endocrinol 2016 · Ammonium succinate (Amberen)

    125 Russian women took Amberen or placebo for 3 months. Many symptom scores and anxiety improved more on Amberen. NAMS notes this research was paid for by the manufacturer.

    Who
    125 women aged 42–60
    Dose
    Amberen (ammonium succinate-based)
    Duration
    3 months
    Result
    Improvement in 13 of 21 Greene symptoms vs placebo; reduced anxiety; estradiol/leptin changes, weight loss.
    Funding
    Not stated in abstract; manufacturer-sponsored per NAMS 2023. Industry-linked

    PubMed · Full text (DOI)

  • Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials.

    Radzinsky VE, Uspenskaya Y, Shulman LP et al. · Obstet Gynecol Int 2019 · Ammonium succinate (Amberen)

    Two identical 90-day Russian trials (227 women) were pooled; Amberen beat placebo on many menopause symptoms. Both trials are manufacturer-linked and have not been repeated independently.

    Who
    227 women (pooled 2 identical RCTs)
    Dose
    Amberen
    Duration
    90 days
    Result
    16 of 21 Greene symptoms improved vs placebo; anxiety down; weight and waist reduced; estradiol rose.
    Funding
    Manufacturer-linked: an author is a paid consultant to Biogix (formerly Lunada Biomedical, Amberen's maker). Industry-linked

    PubMed · Full text (DOI)

  • Multivessel Spontaneous Coronary Artery Dissection: Amberen as a Possible Risk Factor.

    Nesheiwat Z, Mangi MA, Zafrullah F et al. · Cureus 2019 · Ammonium succinate (Amberen)

    A single case report described a rare heart-artery tear in a woman taking Amberen. One case cannot prove cause, but it is worth knowing.

    Who
    1 case
    Dose
    Amberen
    Duration
    n/a
    Result
    Case of multivessel spontaneous coronary artery dissection possibly linked to Amberen.
    Funding
    Case report. Independent / academic

    PubMed · Full text (DOI)

  • Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen(®) and Smart B(®) in Women with Climacteric Syndrome in Perimenopause.

    Kachko VA, Shulman LP, Kuznetsova IV et al. · Adv Ther 2024 · Ammonium succinate (Amberen)

    106 women took Amberen with a companion product, with no placebo group. Symptoms improved over the study, but without a comparison group this cannot show the product caused the change.

    Who
    106 perimenopausal women (open-label, no placebo)
    Dose
    Amberen + Smart B
    Duration
    per paper
    Result
    Greene, anxiety, depression and well-being scores improved from baseline.
    Funding
    Not stated in abstract (product study). Funding not stated

    PubMed · Full text (DOI)

Safety

One case report of spontaneous coronary artery dissection (causality unproven). Trials reported estradiol increase.

Ranked products that contain it

Ranked products containing Ammonium succinate (Amberen), by our score.
ProductAmount per dayScore$/day
Amberen PerimenopauseSuccinate/fumarate blend: amount not disclosed51.7$1.00
Amberen Multi-Symptom Menopause ReliefAmmonium succinate blend (Amber-M Complex): 400 mg50.9$0.83

FAQ

Does Ammonium succinate (Amberen) help with menopause symptoms?

Amberen's ammonium-succinate blend has been studied for common menopause symptoms* in two placebo-controlled trials and one open-label study, all linked to the manufacturer. The amount of each component is not disclosed. Our evidence grade is C. Only manufacturer-linked pooled analysis (2019).

Does The Menopause Society recommend Ammonium succinate (Amberen)?

Not recommended (Level II) – limited, manufacturer-sponsored. The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.

Is Ammonium succinate (Amberen) safe?

One case report of spontaneous coronary artery dissection (causality unproven). Trials reported estradiol increase. Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.

Sources

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.